HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USP potency limits

This article was originally published in The Tan Sheet

Executive Summary

Subcommittee on Nonprescription Drugs and Nutritional Supplements decides to retain its current official upper potency limits for dietary supplements during a March 3 conference call. The subcommittee discussed whether to keep its lower limits at 90% of the labeled amount at a Dec. 8 meeting (1"The Tan Sheet" Dec. 13, 1999, p. 10). However, since many manufacturers must meet a 100% lower potency limit due to FDA regulations, the USP body proposed to include language in the general notices section of the Pharmacopeial Forum stating companies may exceed the USP upper limit by the same percentage with which they exceed its established lower limit. The proposal will appear in the May/June Pharmacopeial Forum where it will be open to public comment

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel